Alkermes (ALKS) News Today $35.19 -0.31 (-0.86%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Hussman Strategic Advisors Inc. Invests $1.93 Million in Alkermes plc (NASDAQ:ALKS)Hussman Strategic Advisors Inc. purchased a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 67,200 shares of the comFebruary 21 at 6:44 AM | marketbeat.comVan ECK Associates Corp Acquires 32,581 Shares of Alkermes plc (NASDAQ:ALKS)Van ECK Associates Corp boosted its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 31.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,567 shares of the company's stock after purchasing an addiFebruary 20 at 3:15 AM | marketbeat.comAlkermes (NASDAQ:ALKS) Hits New 12-Month High - What's Next?Alkermes (NASDAQ:ALKS) Sets New 12-Month High - Should You Buy?February 19 at 10:43 AM | marketbeat.comRice Hall James & Associates LLC Decreases Stock Holdings in Alkermes plc (NASDAQ:ALKS)Rice Hall James & Associates LLC trimmed its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 4.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 429,927 shares of the company's stock aftFebruary 18 at 6:49 AM | marketbeat.comAlkermes (ALKS) Projected to Post Earnings on ThursdayFebruary 18 at 3:59 AM | americanbankingnews.comVontobel Holding Ltd. Sells 7,982 Shares of Alkermes plc (NASDAQ:ALKS)Vontobel Holding Ltd. lowered its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 14.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,279 shares of the company's stock after selling 7,February 18 at 3:36 AM | marketbeat.comHC Wainwright Predicts Alkermes' Q1 Earnings (NASDAQ:ALKS)February 18 at 1:49 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysFebruary 17, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for Alkermes Q1 EarningsAlkermes plc (NASDAQ:ALKS - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Alkermes in a research report issued to clients and investors on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will eFebruary 17, 2025 | marketbeat.comAlkermes' (ALKS) Neutral Rating Reiterated at HC WainwrightFebruary 16, 2025 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) EVP Sells $5,131,207.07 in StockAlkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares of the company's stock, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.February 15, 2025 | marketbeat.comAlkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen NextFebruary 15, 2025 | finance.yahoo.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Alkermes (NASDAQ:ALKS) StockThe Goldman Sachs Group upped their price objective on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday.February 15, 2025 | marketbeat.comAlkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson Sells 144,419 SharesFebruary 15, 2025 | insidertrades.comAlkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at StockNews.comFebruary 15, 2025 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Upgraded by StockNews.com to "Strong-Buy" RatingStockNews.com raised shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday.February 14, 2025 | marketbeat.comAlkermes price target raised to $32 from $30 at Goldman SachsFebruary 13, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)February 13, 2025 | markets.businessinsider.comAlkermes outlook reflects underlying strength, says H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Atricure (ATRC) and Alkermes (ALKS)February 13, 2025 | markets.businessinsider.comAlkermes price target raised to $34 from $33 at BofAFebruary 13, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Alkermes (NASDAQ:ALKS)HC Wainwright restated a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a research note on Thursday.February 13, 2025 | marketbeat.comAlkermes (NASDAQ:ALKS) Hits New 52-Week High Following Earnings BeatFebruary 13, 2025 | americanbankingnews.comAlkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free MilestoneFebruary 13, 2025 | finance.yahoo.comAlkermes (NASDAQ:ALKS) Coverage Initiated at Deutsche Bank AktiengesellschaftFebruary 13, 2025 | americanbankingnews.comAlkermes (ALKS) Projected to Post Quarterly Earnings on ThursdayAlkermes (NASDAQ:ALKS) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662878)February 13, 2025 | marketbeat.comAlkermes reports Q4 non-GAAP EPS $1.05, consensus 76cFebruary 12, 2025 | markets.businessinsider.comAlkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansionFebruary 12, 2025 | msn.comAlkermes plc (ALKS) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comAlkermes plc 2024 Q4 - Results - Earnings Call PresentationFebruary 12, 2025 | seekingalpha.comAlkermes (NASDAQ:ALKS) Sets New 1-Year High on Earnings BeatAlkermes (NASDAQ:ALKS) Sets New 52-Week High After Better-Than-Expected EarningsFebruary 12, 2025 | marketbeat.comAlkermes (NASDAQ:ALKS) Releases Earnings ResultsAlkermes (NASDAQ:ALKS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%.February 12, 2025 | marketbeat.comAlkermes Plc EPS Soars Past ForecastsFebruary 12, 2025 | fool.comAlkermes (NASDAQ:ALKS) Releases FY 2025 Earnings GuidanceAlkermes (NASDAQ:ALKS) updated its FY 2025 earnings guidance. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus estimate of 1.740. The company also issued revenue guidance of $1.3 billionillion-$1.4 billionillion, compared to the consensus estimate of $1.4 billionillion.February 12, 2025 | marketbeat.comAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025February 12, 2025 | prnewswire.comDeutsche Bank Initiates Coverage of Alkermes (ALKS) with Buy RecommendationFebruary 12, 2025 | msn.comUnder Trump, drug price negotiations likely to continueFebruary 11, 2025 | seekingalpha.comAlkermes initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comEarnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 ResultFebruary 11, 2025 | finance.yahoo.comDeutsche Bank sets Alkermes stock Buy rating, $40 targetFebruary 11, 2025 | msn.comAlkermes (NASDAQ:ALKS) Now Covered by Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a report on Tuesday. They set a "buy" rating and a $40.00 price target on the stock.February 11, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)February 10, 2025 | markets.businessinsider.comabrdn plc Decreases Holdings in Alkermes plc (NASDAQ:ALKS)abrdn plc decreased its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 37.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 244,319 shares of the company's stock after selling 148,223 shares during the period. abrdn plc ownedFebruary 9, 2025 | marketbeat.comAlkermes (ALKS) to Release Earnings on WednesdayAlkermes (NASDAQ:ALKS) will be releasing earnings before the market opens on Wednesday, February 12.February 7, 2025 | marketbeat.comUganda: Alks Crowned Champions As Smack League Wraps Up With Thrilling FinaleFebruary 6, 2025 | msn.comAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025February 5, 2025 | prnewswire.comAlkermes plc (NASDAQ:ALKS) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC cut its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 45.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,116 shares of the company's stock after selling 9,2February 5, 2025 | marketbeat.comAlkermes price target raised to $33 from $31 at BofAFebruary 4, 2025 | markets.businessinsider.comRobeco Institutional Asset Management B.V. Raises Holdings in Alkermes plc (NASDAQ:ALKS)Robeco Institutional Asset Management B.V. increased its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 28.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 122,489 shares of the company's stocFebruary 3, 2025 | marketbeat.comCraig C. Hopkinson Sells 100,918 Shares of Alkermes plc (NASDAQ:ALKS) StockFebruary 1, 2025 | insidertrades.com Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Media Mentions By Week ALKS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALKS News Sentiment▼0.480.60▲Average Medical News Sentiment ALKS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALKS Articles This Week▼206▲ALKS Articles Average Week Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exelixis News Exact Sciences News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALKS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
